3Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-seventh edition; Approved Standard. CLSI documents MT-AT. CLSI, 2006.
4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth informational supplement. CLSI documents M100-S18. CLSI/NCCLS,2008.
5Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum- beta - lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother, 2006, 50: 1257-1262.
6Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum- beta -lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology and clinical outcome. Antimicrob Agents Chemether, 2006,50: 498-504.
7Wang H, Kelkar S, Wu W, et al. Clinical Isolates of Enterobacteriaceae Producing Extended-Spectrum beta-lactamases: Prevalence of CTX-M-3 at a Hospital in China. Antimicrob Agents Chemother, 2003, 47:790-793.
8Cai JC, Zhou HW, Zhang R, et al.Emergence of serratia marcescens, klebsiella pneumoniae and escherichia coli possessing the plasmid-mediated carbapenem-hydrolizing beta -lactamase KPC-2 in intensive care units from a Chinese hospital. Antimicrob Agents Chemother, 2008, 52:2014-2018.
